Valeant Pharms Intl patents expiration
1. Apriso patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8865688 | VALEANT PHARMS INTL | Compositions and methods for treatment of bowel diseases with granulated mesalamine |
May, 2030
(6 years from now) | |
Drugs and Companies using MESALAMINE ingredient
Market Authorisation Date: 31 October, 2008
Treatment: For the maintenance of remission of ulcerative colitis
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
APRISO family patents
2. Colazal patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7625884 | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Aug, 2026
(2 years from now) | |
| US7452872 | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Aug, 2026
(2 years from now) | |
|
US7625884 (Pediatric) | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Feb, 2027
(3 years from now) | |
|
US7452872 (Pediatric) | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Feb, 2027
(3 years from now) | |
Drugs and Companies using BALSALAZIDE DISODIUM ingredient
Market Authorisation Date: 18 July, 2000
Treatment: Treatment of ulcerative colitis
Dosage: CAPSULE;ORAL
COLAZAL family patents
3. Giazo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9192616 | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Aug, 2026
(2 years from now) | |
| US7452872 | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Aug, 2026
(2 years from now) | |
| US7625884 | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Aug, 2026
(2 years from now) | |
| US8497256 | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males |
Jun, 2031
(7 years from now) | |
Drugs and Companies using BALSALAZIDE DISODIUM ingredient
Market Authorisation Date: 03 February, 2012
Treatment: Treatment of mildly to moderately active ulcerative colitis in male patients
Dosage: TABLET;ORAL
GIAZO family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic